GLSI

Greenwich LifeSciences is a pre-revenue, clinical-stage biopharma whose entire value rests on one asset: GLSI-100 (GP2 + GM-CSF), an immunotherapy in the Phase III Flamingo-01 trial to prevent HER2/neu breast cancer recurrence. There is no revenue and, per the filing, 'we do not expect to generate revenues for many years, if at all.' The FY2025 net loss widened to $19.4M from $17.4M, driven by an 11% rise in R&D to $17.2M as clinical costs ramp, and management explicitly guides that losses will 'increase' from here. The accumulated deficit is now $87.1M against stockholders' equity of just $353K — a balance sheet that is effectively hollowed out, with liabilities at 7.2x equity and a nonsensical ROE (-5,480%) that simply reflects near-zero book equity.

The decisive problem is liquidity. Cash was $6.18M at year-end 2025 against operating cash burn of $9.91M — under a year of runway at the current pace, and management says burn will rise as they expand Flamingo-01 to 150 sites globally including Europe. The filing is unambiguous: 'Our existing cash will not be sufficient to complete development and obtain regulatory approval,' and simply completing an interim analysis and filing a BLA 'could exceed $30 million.' They funded 2025 almost entirely by selling stock — $11.85M net via the H.C. Wainwright ATM at an average of just $10.85/share — so shares outstanding already grew 10.6% to 14.7M. With the stock at $22 (roughly double the ATM average), expect continued equity issuance at these levels; existing holders should assume ongoing, structural dilution as the base case.